Univercells Overview
- Year Founded
-
2013
- Status
-
Out of Business
- Employees
-
450
- Latest Deal Type
-
Out of Business
Univercells General Information
Description
Developer of vaccines and bio-therapeutics designed to address global health challenges. The company offers integrated biomanufacturing platforms, compact automated RNA/DNA processing technology, single-use high-density production systems, and end-to-end manufacturing services to transform how biologic drugs, vaccines, and therapies are produced and distributed, enabling global biotech and pharmaceutical developers to produce biologics more affordably and make them accessible to patients everywhere.
Contact Information
Website
www.univercells.comCorporate Office
- Avenue Centrale 52
- Zoning de Jumet
- 6040 Gosselies
- Belgium
Corporate Office
- Avenue Centrale 52
- Zoning de Jumet
- 6040 Gosselies
- Belgium
Univercells Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Out of Business | 25-Jun-2026 | Completed | Out of Business | |||
| 13. Later Stage VC | 01-Aug-2023 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series D) | 19-Oct-2022 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 21-Jan-2022 | Completed | Generating Revenue | |||
| 10. Debt - General | 24-Jun-2021 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series C) | 17-Dec-2020 | Completed | Generating Revenue | |||
| 8. Debt - General | 25-Sep-2019 | Completed | Generating Revenue | |||
| 7. Grant | 15-Jun-2019 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 16-Jul-2018 | $18.6M | $25.6M | Completed | Generating Revenue | |
| 5. Grant | 23-Jan-2018 | $2.9M | $6.99M | Completed | Startup |
Univercells Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class D | ||||||||
| Class C | ||||||||
| Class C | ||||||||
| Class B | 483,796 | $36.5 | $36.5 | 1x | $36.5 | 15.07% | ||
| Class A | 304,673 | $22.12 | $22.12 | 1x | $22.12 | 9.49% |
Univercells Comparisons
Industry
Financing
Details
Univercells Competitors (16)
One of Univercells’s 16 competitors is Glycotope, a Formerly VC-backed company based in Berlin, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Glycotope | Formerly VC-backed | Berlin, Germany | ||||
| mAbxience | Corporate Backed or Acquired | Madrid, Spain | ||||
| Cellaion | Formerly VC-backed | Mont-Saint-Guibert, Belgium | ||||
| Biovest International | Formerly VC-backed | Coon Rapids, MN | ||||
| CordenPharma | Private Equity-Backed | Basel, Switzerland |
Univercells Patents
Univercells Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026037882-A2 | Apparatus for culturing shear sensitive cells and related methods | Pending | 14-Aug-2024 | ||
| WO-2026037882-A3 | Apparatus for culturing shear sensitive cells and related methods | Pending | 14-Aug-2024 | ||
| WO-2026013277-A1 | Unit and method for executing a bioprocessing step | Pending | 12-Jul-2024 | ||
| WO-2026012929-A1 | Apparatus for cell culturing and related methods | Pending | 07-Jul-2024 | ||
| EP-4619499-A2 | Systems and methods for recovering target biomolecules from fixed bed bioreactors | Pending | 18-Nov-2022 | C12M27/16 |
Univercells Signals
Univercells Acquisitions (1)
Univercells’s most recent deal was a Merger/Acquisition with SynHelix. The deal was made on 06-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SynHelix | 06-Jan-2022 | Merger/Acquisition | Discovery Tools (Healthcare) |
Univercells Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Quantoom Biosciences | Nivelles, Belgium | 2021 | |
| UNIZIMA | Jumet, Belgium | 2020 | |
| Exothera | Nivelles, Belgium | 2020 | |
| SynHelix | Évry-Courcouronnes, France | 2019 | |
| Rlm Consulting | Nivelles, Belgium | 2006 |
Univercells FAQs
-
When was Univercells founded?
Univercells was founded in 2013.
-
Where is Univercells headquartered?
Univercells is headquartered in Gosselies, Belgium.
-
What is the size of Univercells?
Univercells has 450 total employees.
-
What industry is Univercells in?
Univercells’s primary industry is Holding Companies.
-
Is Univercells a private or public company?
Univercells is a Private company.
-
What is Univercells’s current revenue?
The current revenue for Univercells is .
-
How much funding has Univercells raised over time?
Univercells has raised $239M.
-
Who are Univercells’s competitors?
Glycotope, mAbxience, Cellaion, Biovest International, and CordenPharma are some of the 16 competitors of Univercells.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process